Krupa R Mysore1, Tuan L Phan2,3, Ryan W Himes4, Deborah Schady5, Karen W Eldin6, Bhupesh K Prusty7, Flor M Munoz8. 1. Department of Pediatrics, Section of Pediatric Gastroenterology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA. 2. Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA. 3. HHV-6 Foundation, Santa Barbara, California, USA. 4. Department of Pediatrics, Section of Gastroenterology & Hepatology, Ochsner Medical Center, New Orleans, Louisiana, USA. 5. Department of Pathology, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA. 6. Department of Pathology and Laboratory Medicine, University of Texas Health Science Center at Houston, Houston, Texas, USA. 7. Institut für Virologie und Immunobiologie, Julius-Maximilians Universität Würzburg, Würzburg, Germany. 8. Department of Pediatrics, Section of Infectious Diseases, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas, USA.
Abstract
BACKGROUND: Distinctions between HHV-6 primary infection in seronegative patients and HHV-6 reactivation in seropositive patients remains largely undescribed in pediatric liver transplant (LT) recipients. METHODS: We implemented pretransplant serology testing of HHV-6 in a large pediatric hospital and retrospectively assessed the incidence, manifestations and outcomes of HHV-6 infections over a 3-year period. RESULTS: Among 101 pediatric LT recipients, 96 had pretransplant HHV-6 serologies; 34 (35.4%) were seronegative and 62 (64.6%) seropositive. Posttransplantation, 8/25 (32%) seronegative patients had HHV-6 DNAemia (primary infection) compared to 2/48 (4%) seropositive patients (p=0.002). Compared to seropositive patients, seronegative patients with HHV-6 DNAemia were younger, and had symptoms of fever and/or elevated aminotransferases in association with higher viral loads, in the first month post-transplant. More than 90% of seronegative patients and 77.8% of seropositive patients had HHV-6 detected by PCR in liver biopsy obtained for concerns of allograft rejection, but most had no detectable concomitant DNAemia. Active replication of virus in the liver was confirmed by in situ hybridization in select cases. While HHV-6 infection occurred among patients on prophylaxis doses of antivirals for CMV, HHV-6 DNAemia and presenting symptoms resolved on treatment doses. CONCLUSIONS: HHV-6 DNA-emia occurred more frequently in seronegative pediatric LT recipients, usually in the early posttransplant period, and was subsequently detected in allograft biopsies. HHV-6 cannot be ruled out as a cause of hepatitis in the absence of allograft tissue testing and specialized virological assays, as HHV-6 may disrupt local allograft immune homeostasis while evading traditional screening methods using blood or plasma. The assessment of pre-transplant HHV-6 serological status may be important for risk stratification and post-transplant management of pediatric LT recipients.
BACKGROUND: Distinctions between HHV-6 primary infection in seronegative patients and HHV-6 reactivation in seropositive patients remains largely undescribed in pediatric liver transplant (LT) recipients. METHODS: We implemented pretransplant serology testing of HHV-6 in a large pediatric hospital and retrospectively assessed the incidence, manifestations and outcomes of HHV-6 infections over a 3-year period. RESULTS: Among 101 pediatric LT recipients, 96 had pretransplant HHV-6 serologies; 34 (35.4%) were seronegative and 62 (64.6%) seropositive. Posttransplantation, 8/25 (32%) seronegative patients had HHV-6 DNAemia (primary infection) compared to 2/48 (4%) seropositive patients (p=0.002). Compared to seropositive patients, seronegative patients with HHV-6 DNAemia were younger, and had symptoms of fever and/or elevated aminotransferases in association with higher viral loads, in the first month post-transplant. More than 90% of seronegative patients and 77.8% of seropositive patients had HHV-6 detected by PCR in liver biopsy obtained for concerns of allograft rejection, but most had no detectable concomitant DNAemia. Active replication of virus in the liver was confirmed by in situ hybridization in select cases. While HHV-6 infection occurred among patients on prophylaxis doses of antivirals for CMV, HHV-6 DNAemia and presenting symptoms resolved on treatment doses. CONCLUSIONS: HHV-6 DNA-emia occurred more frequently in seronegative pediatric LT recipients, usually in the early posttransplant period, and was subsequently detected in allograft biopsies. HHV-6 cannot be ruled out as a cause of hepatitis in the absence of allograft tissue testing and specialized virological assays, as HHV-6 may disrupt local allograft immune homeostasis while evading traditional screening methods using blood or plasma. The assessment of pre-transplant HHV-6 serological status may be important for risk stratification and post-transplant management of pediatric LT recipients.
Authors: Philipp Schreiner; Thomas Harrer; Carmen Scheibenbogen; Stephanie Lamer; Andreas Schlosser; Robert K Naviaux; Bhupesh K Prusty Journal: Immunohorizons Date: 2020-04-23
Authors: P Bonnafous; J Marlet; D Bouvet; E Salamé; A-C Tellier; S Guyetant; A Goudeau; H Agut; A Gautheret-Dejean; C Gaudy-Graffin Journal: Am J Transplant Date: 2018-01-27 Impact factor: 8.086
Authors: Julie Fotheringham; Nahid Akhyani; Alexander Vortmeyer; Donatella Donati; Elizabeth Williams; Unsong Oh; Michael Bishop; John Barrett; Juan Gea-Banacloche; Steven Jacobson Journal: J Infect Dis Date: 2006-12-27 Impact factor: 5.226
Authors: Danielle M Zerr; Amalia S Meier; Stacy S Selke; Lisa M Frenkel; Meei-Li Huang; Anna Wald; Margaret P Rhoads; Long Nguy; Rena Bornemann; Rhoda Ashley Morrow; Lawrence Corey Journal: N Engl J Med Date: 2005-02-24 Impact factor: 91.245
Authors: Leonardo Potenza; Mario Luppi; Patrizia Barozzi; Giulio Rossi; Stefania Cocchi; Mauro Codeluppi; Monica Pecorari; Michele Masetti; Fabrizio Di Benedetto; William Gennari; Marinella Portolani; Giorgio Enrico Gerunda; Tiziana Lazzarotto; Maria Paola Landini; Thomas F Schulz; Giuseppe Torelli; Giovanni Guaraldi Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245